ADDISON, Texas, May 31, 2013 /PRNewswire/ -- ULURU Inc. (OTCQB: ULUR) today announced an Altrazeal® expert meeting was held during the European Wound Management Association Conference held in Copenhagen on May 15-17, 2013.
Attending the meeting were physicians, wound care managers, and commercial partners from Europe and Australia. This meeting was designed to introduce physicians and wound care managers to the clinical and economical benefits of Altrazeal® and demonstrate application techniques and provide the science behind the nano-porous material that produces an ideal moist wound healing environment.
The presentation of clinical data clearly demonstrated the clinical and economic benefits of Altrazeal®, including:
- Avoiding lower limb amputation.
- Healing persistent chronic non-healing wounds, in part due to significant pain reduction during treatment with Altrazeal®.
- Transfer from treatment with negative pressure wound therapy to Altrazeal® reduced treatment cost 10 fold and resulted in healing.
- Patient hospitalization avoided due to Altrazeal® treatment.
Commenting on the meeting, Helmut Kerschbaumer, Managing Director of Altrazeal Trading Ltd., stated, "This was an important meeting as it gave us the opportunity to present Altrazeal® to conference participants and commercial partners. The comprehensive presentations were well received by the meeting participants and enabled a greater understanding of advanced wound care, the scientific attributes and the clinical applications of Altrazeal®. The outstanding clinical data presented clearly demonstrated the clinical advantage of Altrazeal® and the potential to dramatically reduce the overall cost of wound care. Similar clinical results and cost savings are routinely reported to us which further confirms the market opportunity for Altrazeal®."
About ULURU Inc.:
ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex® Aggregate technology and OraDisc™ transmucosal delivery system. For further information about ULURU Inc., please visit our website at www.uluruinc.com. For further information about Altrazeal®, please visit our website at www.altrazeal.com.
This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including but not limited to statements made relating to the clinical success and benefits of Altrazeal®. When used in this press release, the words "believe," "expect" and "anticipate" and similar expressions may be indicative of forward-looking statements. These statements by their nature involve substantial risks and uncertainties, certain of which are beyond the Company's control. Any forward-looking statement speaks only as of the date on which such statement is made, and the Company undertakes no obligation to update any forward-looking. These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2012 and other reports filed by us with the Securities and Exchange Commission.
SOURCE ULURU Inc.